Cargando…

Stability Convergence in Antibody Coformulations

[Image: see text] Combined administration of antibody therapeutics has proven to be beneficial for patients with cancer or infectious diseases. As a result, there is a growing trend toward multiple antibodies premixed into a single product form and delivered to patients as a fixed-dose coformulation...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hongyu, Dalby, Paul A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644375/
https://www.ncbi.nlm.nih.gov/pubmed/36264768
http://dx.doi.org/10.1021/acs.molpharmaceut.2c00534
_version_ 1784826728435154944
author Zhang, Hongyu
Dalby, Paul A.
author_facet Zhang, Hongyu
Dalby, Paul A.
author_sort Zhang, Hongyu
collection PubMed
description [Image: see text] Combined administration of antibody therapeutics has proven to be beneficial for patients with cancer or infectious diseases. As a result, there is a growing trend toward multiple antibodies premixed into a single product form and delivered to patients as a fixed-dose coformulation. However, combining antibodies into a single coformulation could be challenging as proteins have the potential to interact and alter their stability and degradation profiles in the mixture, compared to that in isolation. We show that in two specific antibody–antibody coformulations, the more stable antibody component increased the stability of the less stable component, which in return destabilized the more stable component, hence exhibiting an overall convergence of stability in the coformulation.
format Online
Article
Text
id pubmed-9644375
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-96443752022-11-15 Stability Convergence in Antibody Coformulations Zhang, Hongyu Dalby, Paul A. Mol Pharm [Image: see text] Combined administration of antibody therapeutics has proven to be beneficial for patients with cancer or infectious diseases. As a result, there is a growing trend toward multiple antibodies premixed into a single product form and delivered to patients as a fixed-dose coformulation. However, combining antibodies into a single coformulation could be challenging as proteins have the potential to interact and alter their stability and degradation profiles in the mixture, compared to that in isolation. We show that in two specific antibody–antibody coformulations, the more stable antibody component increased the stability of the less stable component, which in return destabilized the more stable component, hence exhibiting an overall convergence of stability in the coformulation. American Chemical Society 2022-10-20 2022-11-07 /pmc/articles/PMC9644375/ /pubmed/36264768 http://dx.doi.org/10.1021/acs.molpharmaceut.2c00534 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Zhang, Hongyu
Dalby, Paul A.
Stability Convergence in Antibody Coformulations
title Stability Convergence in Antibody Coformulations
title_full Stability Convergence in Antibody Coformulations
title_fullStr Stability Convergence in Antibody Coformulations
title_full_unstemmed Stability Convergence in Antibody Coformulations
title_short Stability Convergence in Antibody Coformulations
title_sort stability convergence in antibody coformulations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644375/
https://www.ncbi.nlm.nih.gov/pubmed/36264768
http://dx.doi.org/10.1021/acs.molpharmaceut.2c00534
work_keys_str_mv AT zhanghongyu stabilityconvergenceinantibodycoformulations
AT dalbypaula stabilityconvergenceinantibodycoformulations